Oral candidate shows favourable safety profile and signs of clinical activity in NPDR
Oral candidate shows favourable safety profile and signs of clinical activity in NPDR
Recognising the achievements of this year’s standout healthcare collaborations
The company will initially develop a vaccine to tackle colorectal and pancreatic cancers
Perovial is the first ever hyaluronic acid injectable treatment to be licensed for acute Peyronie’s disease
The US sees around 476,000 new Lyme cases every year
Anaphylaxis is the most serious type of allergic reaction and occurs more commonly in boys
CER‑T therapy shows initial safety signals and prompts protocol expansion
Trial to assess whether once‑weekly treatment can reduce symptomatic viral respiratory infections
siRNA therapeutic progresses in global study for patients with elevated Lp(a)
Company strengthens pipeline with AKTX-102 as it broadens its intellectual property estate
Initiative focuses on population-specific molecular profiling
Company strengthens its neuropsychiatry portfolio after marketing transfer from Recordati
Dawnzera showed an 81% reduction in the four-weekly rate of HAE attacks compared to placebo
Ovarian cancer is the fifth leading cause of deaths from cancer in women
The vaccine could be created as a ready-to-use product, rather than needing to be personalised